drugset / Trial / NCT01110018

GSK573719 IV Enabling Study

NCT01110018

Phase 1 Completed 10 enrolled GlaxoSmithKline
Non-randomizedSingle-groupOpen-labelTreatment

Summary

A single-centre, open-label, sequential, cross-over study to examine the safety, tolerability and pharmacokinetics of 3 ascending single intravenous doses, a single 1000μg oral dose and a single 1000μg inhaled dose of GSK573719 in healthy male volunteers.

Timeline

Start
2010-04-28
Primary completion
2010-06-09
Completion
2010-06-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Umeclidinium Other / unclassified 20 ug Intravenous
Comparator Umeclidinium Other / unclassified 50 ug Intravenous
Comparator Umeclidinium Other / unclassified 100 ug Intravenous
Comparator Umeclidinium Other / unclassified 1000 ug Intravenous